详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

A New Radiopharmaceutical 225 Ac-DOTA-IBA in the Treatment of a Case of Bone Metastases

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University ,Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province ,Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.

出处：

DOI：

ISSN：

关键词： 225Ac bone metastasis DOTA-IBA targeted α-therapy

摘要：

α-Emitter 225 Ac has been considered a candidate for targeted α-therapy. DOTA-IBA is new a precursor targeting bone metastasis. It can be used for radionuclide labeling with 225 Ac. We present a case with refractory bone pain for bone metastasis, who demonstrated an excellent therapy response after 1 cycle of 225 Ac-DOTA-IBA therapy. Moreover, the patient did not have any observable adverse effects.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 3 区核医学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区核医学

第一作者：

第一作者机构： [1]Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University ,Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province ,Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University ,Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province ,Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, People's Republic of China. [*1]Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, No. 25 TaiPing St, Jiangyang District, Luzhou, Sichuan 646000, People's Republic of China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Comparison of the relative diagnostic performance of 68Ga-DOTA-IBA and 18F-NaF for the detection of bone metastasis [2]Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases [3]Safety and Efficacy of Ga-68- or Lu-177-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases A Phase 0/I Study [4]Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer [5]Angiocrine signals regulate quiescence and therapy resistance in bone metastasis. [6]Biocompatible conjugated polymer nanoparticles labeled with 225Ac for tumor endoradiotherapy [7]Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges [8]Nm23-H1 inhibits lung cancer bone-specific metastasis by upregulating miR-660-5p targeted SMARCA5. [9]Survival outcome and prognostic factors for colorectal cancer with synchronous bone metastasis: a population-based study. [10]The TGF-beta signalling negative regulator PICK1 represses prostate cancer metastasis to bone